2006; Bahlmann and Fliser 2009). A single injection of EPO has been shown to exert a renoprotective effect in some acute kidney disease models, but it had not been fully clarified whether that ability could extend to halting progression of chronic kidney disease. To address this issue, we selected a unique model with which we could evaluate the progression of CKD after applying treatment only in the acute phase of the disease. In fact, it has been reported that an initial treatment with anti‐PDGF antibody could halt progression of CKD in this model (Ostendorf et al. 2001; Tsuji et al. 2006). Here, EPO is linked to chronic kidney disease.